Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €129.43 EUR
Change Today +0.12 / 0.09%
Volume 103.0
ACT On Other Exchanges
SIX Swiss Ex
As of 6:08 AM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).

actelion ltd-reg (ACT) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/28/15 - €129.88
52 Week Low
05/28/14 - €70.82
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ACTELION LTD-REG (ACT)

Related News

No related news articles were found.

actelion ltd-reg (ACT) Related Businessweek News

No Related Businessweek News Found

actelion ltd-reg (ACT) Details

Actelion Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for diseases with unmet medical needs. It offers Tracleer, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension (PAH), a chronic and life-threatening disorder that severely compromises the functions of the lungs and heart; and Opsumit, an orally available endothelin receptor antagonist for the treatment of PAH to delay disease progression. The company also provides Veletri, an intravenous prostacyclin for the treatment of PAH to enhance exercise capacity; and Ventavis, an inhaled synthetic analog of prostacyclin for the treatment of PAH to enhance a composite endpoint consisting of exercise tolerance, symptoms, and lack of deterioration. In addition, it offers Valchlor, a chemotherapeutic agent for the treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients; and Zavesca, an oral treatment for patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is unsuitable. Actelion Ltd markets its products in Switzerland, the United States, Europe, Japan, China, Russia, Mexico, and internationally. The company was founded in 1997 and is headquartered in Allschwil, Switzerland.

Founded in 1997

actelion ltd-reg (ACT) Top Compensated Officers

Founder, Chief Executive Officer, Member of M...
Total Annual Compensation: SFr.2.7M
Compensation as of Fiscal Year 2014.

actelion ltd-reg (ACT) Key Developments

Actelion Ltd. Approves Dividend, Payable on 15 May 2015

Actelion Ltd. announced that a proposal by the Board to distribute as dividend out of legal reserve originating from capital contribution in the amount of CHF 1.30 per registered share was passed by shareholders. The ex-dividend date will be 12 May 2015 and the payment will be made on 15 May 2015.

Actelion Ltd. Presents at Bio-Trinity, May-12-2015 10:10 AM

Actelion Ltd. Presents at Bio-Trinity, May-12-2015 10:10 AM. Venue: Novotel London West, 1 Shortlands, London W6 8DR, United Kingdom. Speakers: Nicholas Franco, Chief Business Development Officer, Executive Vice President and Member of the Management Board.

Actelion Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for 2015

Actelion Ltd. reported earnings results for the first quarter ended March 31, 2015. For the period, the company reported c ore operating income of CHF 218 million, core net income of CHF 185 million or CHF 1.61 per diluted share against core operating income of CHF 189 million, core net income of CHF 170 million or CHF 1.46 per diluted share a year ago. Operating income was CHF 190 million compared to CHF 153 million a year ago. Revenues were CHF 515 million compared to CHF 469 million a year ago. Operating cash inflow was CHF 94 million compared to CHF 96 million a year ago. The company reported net income of CHF 159 million, or CHF 1.38 per diluted share compared to CHF 128 million or CHF 1.09 per diluted share for the same quarter a year ago. Operating income was CHF 190 million, compared to CHF 153 million for the same quarter a year ago. Capital expenditure was CHF 7 million against CHF 6 million a year ago. Income before income tax expense was CHF 183 million. The company is now confident that, barring unforeseen events, core earnings growth for 2015 will be in the low double-digit percentage range, at constant exchange rates and excluding the benefit of 2014 US rebate reversals.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACT:GR €129.43 EUR +0.12

ACT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Endo International PLC $83.41 USD +0.24
H Lundbeck A/S kr134.40 DKK +0.30
Hikma Pharmaceuticals PLC 2,111 GBp +19.00
UCB SA €64.58 EUR +1.12
View Industry Companies

Industry Analysis


Industry Average

Valuation ACT Industry Range
Price/Earnings 25.4x
Price/Sales 7.6x
Price/Book 7.9x
Price/Cash Flow 22.7x
TEV/Sales 7.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACTELION LTD-REG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at